Abiopharma

🔍 Farkas K Christopher (Executive)

Company: CURTISS WRIGHT CORP (CW)

Report Date: 2026-03-16

Detailed Transactions and Holdings:

• Acquired 2,183 shares of Common Stock (Direct)
  Date: 2026-03-16 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,436.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 918 shares of Common Stock at $677.46 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,518.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 2,183 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-16 | Code: M | Expires: 2026-03-16 | Exercise: 2026-03-16 | equity_swap_involved: 0 | shares_owned_after: 9,366.00 | transaction_form_type: 4 | Footnotes: F2, F1, F2, F5

Footnotes:

• F1: These shares were acquired through a restricted stock unit ("RSU") grant under the Company's 2014 Omnibus Incentive Plan on March 16, 2023. The RSUs cliff vested in Issuer common stock after a three-year vesting period from the date of grant.
• F2: No price on the date of issue. The restricted stock units were granted as an employee benefit transaction.
• F3: Shares were sold in compliance with the Company's share ownership guidelines whereby the Reporting Person may sell a portion of the vesting award to cover any tax obligations associated with the vesting of the award. The Reporting Person is and remains in compliance with the share ownership guidelines.
• F4: The price reported is the average selling price. The shares were sold in multiple transactions at prices ranging from $669.72 to $681.43, inclusive. The Reporting Person undertakes to provide the SEC, the issuer and any security holder full information regarding the number of shares sold at each separate price.
• F5: Share total includes dividend credits earned on prior outstanding grants.